as a minimally invasive procedure and novel technique for the treatment of RCC. Conclusions: To our knowledge, this is the first case to date of bilateral RCC treated with simultaneous retroperitoneal laparoscopic nephron-sparing surgery (RLNSS). Here we indicate the feasibility of this management and discuss the advantages and disadvantages of this technique. Background: This study investigated the role of ZEB1 in vasculogenic mimicry (VM) formation and the interplay between VM and epithelial-mesenchymal transition (EMT). Methods: Ninety-two prostate cancer tissue specimens were stained by CD34 and periodic acid Schiff. Then, we stained ZEB1 protein in the consecutive sections. Moreover, prostate cancer cells were subjected to ZEB1 knockdown using ZEB1 siRNA and then to 3D culture assay. EMT related maker was also evaluated. Results: The data showed that the presence of VM and high ZEB1 expression were associated with higher Gleason score, TNM stage, and lymph node and distant metastases. ZEB1 knockdown reduced VM formation and the expression of EMT-related in prostate cancer cells. Conclusions: In the current study was the first to reveal that ZEB1 played an important role in VM formation in prostate cancer ex vivo and in vitro. Mechanistically, this process may have a relationship with EMT. 
amount of 125I, reaction time, pH, and reaction volume on the labeling rate of the 125I-RSOAds-hTERT/PSA oncolytic adenovirus marker were measured. Radioactive oncolytic adenoviruses were isolated and purified by column chromatography; the radiochemical purities of the 125I-RSOAds-hTERT/PSA marker at different times were detected by paper chromatography. After the addition of radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses to prostate cancer cells, changes in the inhibitory rate were measured by methylthiazolyldiphenyltetrazolium bromide (MTT) assays. Results: The radiochemical purity of the 125I-RSOAdshTERT/PSA marker was >95%, and the marker was stable (93-94%) after storage at 4 ℃ for 7 days. The optimal conditions were 0. Comparing with normal group, ErbB3 protein of urothelium carcinoma group has a higher expression and prostate cancer group has a lower expression on the contrary. The contents of ErbB3 protein in urinary calculus group and BPH group had no significantly differences with
